根治性前列腺切除术后高危特征前列腺癌立体定向体部放疗的II期试验初步分析
这项前瞻性II期试验在2018年5月至2020年5月纳入41例根治性前列腺切除术后患者,分辅助、挽救和寡转移三组接受前列腺床SBRT 30-32 Gy/5次。中位随访23个月,无3级及以上胃肠或泌尿生殖毒性,2年临床疾病控制率95%、生化控制率73%。
要点
- 前列腺床SBRT 30-32 Gy分5次,未出现3级及以上胃肠或泌尿生殖毒性。
- 基线校正后急性和晚期2级泌尿生殖毒性(尿失禁)率分别为2.4%(1/41)和12.2%(5/41)。
- 2年临床疾病控制率95%、生化控制率73%,2例临床失败分别为区域淋巴结和骨转移。
核心结论
- 根治性前列腺切除术后SBRT在本前瞻性队列中耐受性很好,对放疗后生活质量指标无显著影响,同时提供了极好的临床疾病控制。
研究设计与样本
- 前瞻性II期试验,2018年5月至2020年5月纳入41例符合入选标准的根治性前列腺切除术后患者。
- 患者分层为3组:I组(辅助)PSA<0.2 ng/mL且具有高危特征(切缘阳性、精囊侵犯或包膜外侵犯);II组(挽救)PSA≥0.2 ng/mL但<2 ng/mL;III组(寡转移)PSA≥0.2 ng/mL但<2 ng/mL且最多3处淋巴结或骨转移。
- I组不接受雄激素剥夺治疗;II组接受6个月雄激素剥夺治疗;III组接受18个月雄激素剥夺治疗。
- 前列腺床SBRT剂量为30至32 Gy分5次。
主要发现
- 中位随访23个月(范围10-37)。
- SBRT为辅助治疗8例(20%),挽救治疗28例(68%),挽救治疗且存在寡转移5例(12%)。
- 泌尿、肠道和性生活质量域在SBRT后保持高位。
- 患者耐受SBRT,无3级及以上胃肠或泌尿生殖毒性。
- 基线校正后急性和晚期2级泌尿生殖毒性(尿失禁)率分别为2.4%(1/41)和12.2%(5/41)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are limited data regarding using stereotactic body radiation therapy (SBRT) in the postprostatectomy setting. Here, we present a preliminary analysis of a prospective phase II trial that aimed to evaluate the safety and efficacy of postprostatectomy SBRT for adjuvant or early salvage therapy. MATERIALS AND METHODS: Between May 2018 and May 2020, 41 patients fulfilled inclusion criteria and were stratified into 3 groups: group I (adjuvant), prostate-specific antigen (PSA) < 0.2 ng/mL with high-risk features including positive surgical margins, seminal vesicle invasion, or extracapsular extension; group II (salvage), with PSA ≥ 0.2 ng/mL but < 2 ng/mL; or group III (oligometastatic), with PSA ≥ 0.2 ng/mL but < 2 ng/mL and up to 3 sites of nodal or bone metastases. Androgen deprivation therapy was not offered to group I. Androgen deprivation therapy was offered for 6 months for group II and 18 months for group III patients. SBRT dose to the prostate bed was 30 to 32 Gy in 5 fractions. Baseline-adjusted physician reported toxicities (Common Terminology Criteria for Adverse Events), patient reported quality-of-life (Expanded Prostate Index Composite, Patient-Reported Outcome Measurement Information System), and American Urologic Association scores were evaluated for all patients. RESULTS: The median follow-up was 23 months (range, 10-37). SBRT was adjuvant in 8 (20%) patients, salvage in 28 (68%), and salvage with the presence of oligometastases in 5 (12%) patients. Urinary, bowel, and sexual quality of life domains remained high after SBRT. Patients tolerated SBRT with no grade 3 or higher (3+) gastrointestinal or genitourinary toxicities. The baseline adjusted acute and late toxicity grade 2 genitourinary (urinary incontinence) rate was 2.4% (1/41) and 12.2% (5/41). At 2 years, clinical disease control was 95%, and biochemical control was 73%. Among the 2 clinical failures, 1 was a regional node and the other a bone metastasis. Oligometastatic sites were salvaged successfully with SBRT. There were no in-target failures. CONCLUSIONS: Postprostatectomy SBRT was very well tolerated in this prospective cohort, with no significant effect on quality of life metrics postirradiation, while providing excellent clinical disease control.
引用
- Laughlin BS, Voss MM, Toesca DAS, et al. Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy. Adv Radiat Oncol. 2022. PMID: 36845611. doi:10.1016/j.adro.2022.101143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。